© 2025 Replicate Bioscience | All rights reserved.
A segment of yellow, single-stranded RNA arcs across the right side of the page. Behind it is a blue-to-teal background overlaid with rows of simple human silhouettes. A bright white light trail animates following the arch of the RNA.
A segment of yellow, single-stranded RNA arcs across the right side of the page. Behind it is a blue-to-teal background overlaid with rows of simple human silhouettes. A bright white light trail animates following the arch of the RNA.

The Power of RNA Amplified

Impact measured in billions.

YOUR CELLs’ vERY OWN COPY MACHINERY

Our platform leverages next-generation self-replicating RNA (srRNA) vectors. Once inside cells, the genetic code of our srRNA drives repeated production of natural RNA, resulting in outsized protein expression and durable therapeutic effect.

OUR SCIENCe
A strand of srRNA floats upwards to the right. Behind it, copied mRNA segments are visible.
A strand of srRNA floats upwards to the right. Behind it, copied mRNA segments are visible.

ENABLING BROAd APPLICATIONs FOR RNA TREATMENTs

Replicate is advancing a robust pipeline of srRNA treatments spanning several therapeutic areas, including infectious disease, oncology, and autoimmune disorders. Improved performance over linear mRNA lets us help even more patients.

PIPELINe
A simple blue line-drawing pattern of human silhouettes arranged in three rows.
A simple blue line-drawing pattern of human silhouettes arranged in three rows.
A gradient blue background with a white, curved, light trail.
A gradient blue background with a white, curved, light trail.

News & Publications

12.16.25 Press Releases
Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer
Read more
12.04.25 Press Releases
Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America
Read more
09.24.25 Publications & Presentations
Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000
Read more
VIEW ALL NEWs